<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992797</url>
  </required_header>
  <id_info>
    <org_study_id>AUS-KIB-001</org_study_id>
    <nct_id>NCT00992797</nct_id>
  </id_info>
  <brief_title>Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity</brief_title>
  <acronym>DIVINE</acronym>
  <official_title>A Randomized Controlled Trial of the Effect of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes of Nordic and Sub-Indian Ethnicity .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Aker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Aker</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this 6 months study is to evaluate the metabolic effects of 400.000-600.000 IU of
      vitamin D supplementation in subjects with type 2 diabetes and hypovitaminosis D. The main
      hypothesis is that subjects with low levels of 25-OH-vitamin D will benefit from
      supplementation with cholecalciferol in sufficient doses to optimize serum levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accumulating evidence suggests that hypovitaminosis D may be associated with the development
      of type 2 diabetes and disturbances in glucose and insulin metabolism. There is lack of data
      from randomized, controlled studies of sufficient duration and with the use of sufficient
      doses of vitamin D to assess the importance of vitamin D supplementation in glucose
      metabolism in type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity measured with euglycemic, hyperinsulinemic clamp</measure>
    <time_frame>Before and after the 6 months intervention period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion measured with IVGTT</measure>
    <time_frame>At 0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity/muscle strength</measure>
    <time_frame>At 0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c and fasting glucose</measure>
    <time_frame>At 0, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>At 0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in inflammatory markers, endothelial function and bone specific laboratory markers.</measure>
    <time_frame>At 0, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of this regimen of vitamin D3 supplementation; subjects will be assessed for hypercalcemia and renal dysfunction.</measure>
    <time_frame>Entire intervention period, samples taken at 0,1,3, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life score between groups (SF-36).</measure>
    <time_frame>At 0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on serum lipid levels and other biochemical markers</measure>
    <time_frame>At 0, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics analyses.</measure>
    <time_frame>At 0 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D &lt; 100 nmol/L. If serum 25(OH)D &gt; 100 placebo will be given. The cholecalciferol will be given in orange juice.</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Vitamin D</other_name>
    <other_name>ZymaD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orange juice</intervention_name>
    <description>Orange juice at randomization day and at week 5.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Moderate (S-25OHD 25-50 nmol/l) to severe (S-25OHD &lt; 25 nmol/l) vitamin D deficiency
             measured at Visit 1.

          2. Patients with type 2 diabetes, including drug naïve subjects, subjects using oral
             anti-diabetic medication and subjects on insulin treatment. All medication must be in
             stable doses during the 4 week lead-in period.

          3. HbA1c &lt; 11 % at Visit 1.

          4. Able to communicate in Norwegian.

          5. Men and women ≥ 18 years.

          6. Norwegian or South Asian ethnicity.

          7. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study. All WOCBP must have negative
             serum or urine pregnancy test at enrollment, randomization, titration visit and final
             study assessment.

          8. Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone
             replacement therapy, multivitamin supplements and nutritional supplements are allowed
             if the subjects adhere to the same regimen during the study

        Exclusion Criteria:

          1. Subjects not having type 2 diabetes.

          2. SBP ≥ 160 or DBP ≥ 95 at Visit 1.

          3. Significant renal disease or chronic renal impairment, GFR&lt; 30 ml/min.

          4. Significant liver disease or ASAT or ALAT &gt;3x UNL.

          5. Malignancy during the last five years.

          6. Hypercalcemia at Visit 1.

          7. A history of kidney stone disease

          8. WOCBP unwilling or unable to use an acceptable method to avoid pregnancy.

          9. Pregnant or breastfeeding women.

         10. Chronic inflammatory disease in active phase

         11. Long term (&gt;2 weeks) use of corticosteroids last 3 months

         12. Mental condition (psychiatric or organic cerebral disease) rendering the subject
             unable to understand the nature, scope and possible consequences of the study.

         13. Drug or alcohol abuse.

         14. BMI &gt; 45 kg/m2 or bariatric surgery (&lt;5 years).

         15. Anemia

         16. Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke)
             during the last 6 months.

         17. Any medical condition that in the judgment of the investigator would jeopardize the
             subject's safety or evaluation of the study drug for efficacy and safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kåre I Birkeland, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Aker</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulseth Wium, MD</last_name>
    <phone>4722894745</phone>
    <email>diabeteslab@aus.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Laboratory, Oslo University Hospital Aker</name>
      <address>
        <city>Oslo</city>
        <zip>0514</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4722894745</phone>
      <email>diabeteslab@aus.no</email>
    </contact>
    <investigator>
      <last_name>Kåre I Birkeland, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>November 2, 2009</last_update_submitted>
  <last_update_submitted_qc>November 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director of Research Tomm Bernklev</name_title>
    <organization>Oslo University Hospital, Aker</organization>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin secretory dysfunction</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Vascular stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

